Lung Cancer, Small Cell
Conditions
Keywords
chemonaive, small cell lung cancer, untreated, Lung cancer, HYCAMTIN, first-line, extensive disease
Brief summary
This study was designed to find the safest and most effective dose of a combination of two chemotherapy drugs, Hycamtin® (topotecan) and Paraplatin® (carboplatin), in people with extensive disease small cell lung cancer.
Interventions
DRUGtopotecan
Hycamtin and Carboplatin as first-line treatment of chemonaive subjects with EX-SCLC.
DRUGcarboplatin
Hycamtin and Carboplatin as first-line treatment of chemonaive subjects with EX-SCLC.
Sponsors
GlaxoSmithKline
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adequate contraception methods include: systemic contraceptives or IUD for 3 months prior to start of the study medication or diaphragm plus spermicide; for males, condom plus spermicide; or total abstinence from sexual intercourse during the course of the study * Women of childbearing potential and sexually active males must practice or use an accepted and effective form of contraception * Subjects who present with CNS metastases are eligible, provided the attending physician ascertains that the metastases are controlled before the start of chemotherapy, and the subject is asymptomatic on neurologic exam and is not receiving corticosteroid therapy to control symptoms. Continued use of other anti-seizure medication is permitted * Free of active infection * At screening, a probable life expectancy of at least 3 months * No prior chemotherapy for SCLC or any chemotherapy within 5 years of the diagnosis of SCLC. Prior radiation to any symptomatic site is permitted provided that the indicator lesion site(s) are not irradiated, and radiation is completed before chemotherapy is started * Performance status ECOG 0-1 * Adequate hematologic, renal and hepatic function •Hematologic: ANC 1500/mm3 \[1.5 x 109/L\], platelet count 100,000/L (100 x 109/L), hemoglobin 9.0 g/dL * Renal: Serum Creatinine ≤1.5mg/dL (133mol/L) and CrCl 60 ml/min (Cockroft-Gault) \[Cockroft, 1976\] CrCl may be calculated using the Cockcroft-Gault formula: CrCl (ml/min) = Q x (140-age \[yr\]) x body wt \[kg\] 72 x serum creatinine \[mg/dl\] Q = 0.85 for females Q = 1.0 for males CrCl (ml/min) = K x (140-age \[yr\]) x body wt \[kg\] Serum creatinine \[mol/L\] K = 1.0 for females K = 1.23 for males * Hepatic: Serum bilirubin (1.5 mg/dL), SGOT (AST), SGPT (ALT) and Alkaline Phosphatase 2 times the upper limit of normal (ULN) if liver metastases are absent by abdominal CT or MRI, or 5 times ULN if liver metastases are present * At least 18 years old * Written informed consent (subject's written understanding of and agreement to participate in this study. * Subject with histologically-confirmed extensive small cell lung cancer or unequivocally positive positive cytological evidence (sputum, at least two, or aspirate biopsy) * Presence of measurable disease according to World Health Organization (WHO)\* criteria, as determined by diagnostic tests, including CT scan of the chest and abdomen, or MRI scan of the brain, or CXR, or PET CT, MRI, and/or CXR are the preferred diagnostic methods to evaluate disease during the course of this study. Use of positron-emission tomography (PET) is not required, but is permitted if it is the standard diagnostic tool employed by the institution. Measurable disease - Presence of at least one bidimensionally measurable, non-CNS lesion (indicator lesion). If the measurable disease is restricted to a solitary lesion, its neoplastic nature should be confirmed by cytology/histology • Measurable disease, either on CT or MRI scan, requires one diameter 1 cm and one diameter 2 cm. • Measurable disease on CXR requires both diameters 2 cm. • Palpable tumor masses that could not be evaluated radiologically require two diameters 2 cm * At least 3 weeks since last major surgery (a lesser period is acceptable if decided to be in the best interest of the subject). * Subjects with central nervous system metastases are eligible as long as the attending doctor determines that the metastases are under control before the start of chemotherapy, and the subject has no symptoms of spreading of disease to the brain, and is not receiving drugs called steroids to control the symptoms. * Laboratory criteria: Subjects must have adequate bone marrow reserve and adequate kidney and liver function.
Exclusion criteria
* Concurrent or planned chemotherapy, immunotherapy, radiotherapy, or investigational therapy for the treatment of SCLC. (Concurrent radiation for palliation of bone metastases and CNS lesions must be discussed with and approved by the GlaxoSmithKline Medical Monitor) * Concurrent severe medical problems other than the diagnosis of SCLC, which would significantly limit full compliance with the study or expose the patient to extreme risk * Concomitant malignancies or previous malignancies other than SCLC within the last 5 years, with the exception of adequately treated basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, or localized low grade prostate cancer (contact GlaxoSmithKline Medical Monitor to discuss enrolment of subjects with low grade prostate cancer) * Present clinical signs or symptoms of brain and/or leptomeningeal metastases confirmed by CT or MRI brain scan, or corticosteroid treatment to control symptoms of brain metastases * Uncontrolled infection * Ongoing tumor or previous tumor other than lung cancer within the last 5 years. * Symptoms of spreading of the disease to the brain that requires treatment with drugs called steroids * Severe medical problems other than the diagnosis of SCLC that would limit the ability of the subject to follow study plan or that would expose the subject to extreme risk. * Ongoing or planned chemotherapy, immunotherapy, radiation treatment, or other experimental drug therapy for the treatment of SCLC. * Use of investigational drug within 30 days or 5 half-lives (whichever is longer) preceding the first dose of study medication * Women who are pregnant or lactating. * Women who can become pregnant who refuse to practice an adequate form of birth control. * Subjects with history of allergic reaction to chemicals related to HYCAMTIN and PARAPLATIN. * Subjects with pre-existing heart disease, such as congestive heart failure, irregular heartbeats that require treatment, and heart attack within the last 3-months.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Response Rate, as Determined by Radiologic Evaluation (Utilizing the World Health Organization [WHO] Criteria), Calculated as the Number of Participants With the Indicated Response | Baseline until up to Day 169 | The categories of tumor response were: complete response (complete disappearance of all known lesions determined by 2 measurements not less than 4 weeks apart), partial response (\>50% decrease in measurable lesions for at least 4 weeks with no appearance of new lesions), stable disease (no change in tumor size for at least 8 weeks), progressive disease (\>25% increase in measurements of lesions or appearance of new lesions), and not evaluable. The overall response rate was determined using a scan performed within the first 30 days of the first response. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Response Duration | From time of partial or complete response to disease progression/death | Duration of response is calculated as the time from first documented partial or complete response until first documented sign of disease progression or death. The study was terminated after the dose-finding run-in component was completed because of slow recruitment and acknowledgement of a competing Phase II study. Data not available. |
| Time to Progression | From start of treatment to disease progression/death | Time to progression is defined as the time from the start of treatment until the first documented sign of disease progression or death due to any cause, if sooner. The study was terminated after the dose-finding run-in component was completed because of slow recruitment and acknowledgement of a competing Phase II study. Data not available. |
| Overall Survival, Calculated as the Number of Subjects Who Died From the Start of Treatment Until Follow-up | Week 1 up to maximum of Day 519 | Overall survival is defined as the time from the start of treatment until death due to any cause. The study was terminated after the dose-finding run-in component was completed because of slow recruitment and acknowledgement of a competing Phase II study. Data not available, as the activity stage of the study was not conducted. |
| Time to Response | From start of treatment to evidence of partial or complete response | Time to response is calculated as the time from the start of treatment until first documented evidence of partial or complete response. The study was terminated after the dose-finding run-in component was completed because of slow recruitment and acknowledgement of a competing Phase II study. Data not available, as the activity stage was not done. |
| Grade 2 (Moderate) Hematological Toxicities | Week 1 through Endpoint (variable based on disease progression or toxicity | Hematology evaluation included hemoglobin, hematocrit, red blood cell count, white blood cell with differential and platelet count. Differential included neutrophils, bands, lymphocytes, monocytes, eosinophils, and basophils. The intensity of each hematological toxicity was assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAEs). Hematological toxicities are summarized by Common Terminology Criteria (CTC) V3.0 Maximum Toxicity Grade. |
| Grade 3 (Severe) Hematological Toxicities | Week 1 through Endpoint (variable based on disease progression or toxicity | Hematology evaluation included hemoglobin, hematocrit, red blood cell count, white blood cell with differential and platelet count. Differential included neutrophils, bands, lymphocytes, monocytes, eosinophils, and basophils. The intensity of each hematological toxicity was assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAEs). Hematological toxicities are summarized by Common Terminology Criteria (CTC) V3.0 Maximum Toxicity Grade. |
| Grade 4 (Life-threatening or Disabling) Hematological Toxicities | Week 1 through Endpoint (variable based on disease progression or toxicity | Hematology evaluation included hemoglobin, hematocrit, red blood cell count, white blood cell with differential and platelet count. Differential included neutrophils, bands, lymphocytes, monocytes, eosinophils, and basophils. The intensity of each hematological toxicity was assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAEs). Hematological toxicities are summarized by Common Terminology Criteria (CTC) V3.0 Maximum Toxicity Grade. |
| Grade 1 (Mild) Hematological Toxicities | Week 1 through Endpoint (variable based on disease progression or toxicity) | Hematology evaluation included hemoglobin, hematocrit, red blood cell count, white blood cell with differential and platelet count. Differential included neutrophils, bands, lymphocytes, monocytes, eosinophils, and basophils. The intensity of each hematological toxicity was assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAEs). Hematological toxicities are summarized by Common Terminology Criteria (CTC) V3.0 Maximum Toxicity Grade. |
Countries
Poland, United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Intravenous Topotecan and Carboplatin Administered Weekly (Days 1 and 8 for topotecan; Day 1 for carboplatin) every 21 days | 33 |
| Total | 33 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Adverse Event | 6 |
| Overall Study | Disease Progression | 4 |
| Overall Study | Lost to Follow-up | 1 |
| Overall Study | Other | 1 |
Baseline characteristics
| Characteristic | Intravenous Topotecan and Carboplatin |
|---|---|
| Age, Continuous | 62.2 years STANDARD_DEVIATION 9.45 |
| Race/Ethnicity, Customized White | 33 participants |
| Sex: Female, Male Female | 8 Participants |
| Sex: Female, Male Male | 25 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 33 / 33 |
| serious Total, serious adverse events | 6 / 33 |
Outcome results
Primary
Overall Response Rate, as Determined by Radiologic Evaluation (Utilizing the World Health Organization [WHO] Criteria), Calculated as the Number of Participants With the Indicated Response
The categories of tumor response were: complete response (complete disappearance of all known lesions determined by 2 measurements not less than 4 weeks apart), partial response (\>50% decrease in measurable lesions for at least 4 weeks with no appearance of new lesions), stable disease (no change in tumor size for at least 8 weeks), progressive disease (\>25% increase in measurements of lesions or appearance of new lesions), and not evaluable. The overall response rate was determined using a scan performed within the first 30 days of the first response.
Time frame: Baseline until up to Day 169
Population: ITT (Intent to Treat): participants that received at least one dose of study drug
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Intravenous Topotecan and Carboplatin | Overall Response Rate, as Determined by Radiologic Evaluation (Utilizing the World Health Organization [WHO] Criteria), Calculated as the Number of Participants With the Indicated Response | Complete Response | 0 Participants |
| Intravenous Topotecan and Carboplatin | Overall Response Rate, as Determined by Radiologic Evaluation (Utilizing the World Health Organization [WHO] Criteria), Calculated as the Number of Participants With the Indicated Response | Partial Response | 8 Participants |
| Intravenous Topotecan and Carboplatin | Overall Response Rate, as Determined by Radiologic Evaluation (Utilizing the World Health Organization [WHO] Criteria), Calculated as the Number of Participants With the Indicated Response | Stable Disease | 11 Participants |
| Intravenous Topotecan and Carboplatin | Overall Response Rate, as Determined by Radiologic Evaluation (Utilizing the World Health Organization [WHO] Criteria), Calculated as the Number of Participants With the Indicated Response | Progressive Disease | 6 Participants |
| Intravenous Topotecan and Carboplatin | Overall Response Rate, as Determined by Radiologic Evaluation (Utilizing the World Health Organization [WHO] Criteria), Calculated as the Number of Participants With the Indicated Response | Not Evaluable | 8 Participants |
Secondary
Grade 1 (Mild) Hematological Toxicities
Hematology evaluation included hemoglobin, hematocrit, red blood cell count, white blood cell with differential and platelet count. Differential included neutrophils, bands, lymphocytes, monocytes, eosinophils, and basophils. The intensity of each hematological toxicity was assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAEs). Hematological toxicities are summarized by Common Terminology Criteria (CTC) V3.0 Maximum Toxicity Grade.
Time frame: Week 1 through Endpoint (variable based on disease progression or toxicity)
Population: ITT Population (i.e., participants who had at least one dose of study medication)
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Intravenous Topotecan and Carboplatin | Grade 1 (Mild) Hematological Toxicities | Anemia | 12 participants |
| Intravenous Topotecan and Carboplatin | Grade 1 (Mild) Hematological Toxicities | Neutropenia | 1 participants |
| Intravenous Topotecan and Carboplatin | Grade 1 (Mild) Hematological Toxicities | Thrombocytopenia | 15 participants |
| Intravenous Topotecan and Carboplatin | Grade 1 (Mild) Hematological Toxicities | Leukopenia | 13 participants |
Secondary
Grade 2 (Moderate) Hematological Toxicities
Hematology evaluation included hemoglobin, hematocrit, red blood cell count, white blood cell with differential and platelet count. Differential included neutrophils, bands, lymphocytes, monocytes, eosinophils, and basophils. The intensity of each hematological toxicity was assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAEs). Hematological toxicities are summarized by Common Terminology Criteria (CTC) V3.0 Maximum Toxicity Grade.
Time frame: Week 1 through Endpoint (variable based on disease progression or toxicity
Population: ITT Population (i.e., participants who had at least one dose of study medication)
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Intravenous Topotecan and Carboplatin | Grade 2 (Moderate) Hematological Toxicities | Anemia | 14 participants |
| Intravenous Topotecan and Carboplatin | Grade 2 (Moderate) Hematological Toxicities | Neutropenia | 4 participants |
| Intravenous Topotecan and Carboplatin | Grade 2 (Moderate) Hematological Toxicities | Thrombocytopenia | 5 participants |
| Intravenous Topotecan and Carboplatin | Grade 2 (Moderate) Hematological Toxicities | Leukopenia | 10 participants |
Secondary
Grade 3 (Severe) Hematological Toxicities
Hematology evaluation included hemoglobin, hematocrit, red blood cell count, white blood cell with differential and platelet count. Differential included neutrophils, bands, lymphocytes, monocytes, eosinophils, and basophils. The intensity of each hematological toxicity was assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAEs). Hematological toxicities are summarized by Common Terminology Criteria (CTC) V3.0 Maximum Toxicity Grade.
Time frame: Week 1 through Endpoint (variable based on disease progression or toxicity
Population: ITT population (i.e., participants who had at least one dose of study medication)
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Intravenous Topotecan and Carboplatin | Grade 3 (Severe) Hematological Toxicities | Anemia | 4 participants |
| Intravenous Topotecan and Carboplatin | Grade 3 (Severe) Hematological Toxicities | Neutropenia | 4 participants |
| Intravenous Topotecan and Carboplatin | Grade 3 (Severe) Hematological Toxicities | Thrombocytopenia | 2 participants |
| Intravenous Topotecan and Carboplatin | Grade 3 (Severe) Hematological Toxicities | Leukopenia | 4 participants |
Secondary
Grade 4 (Life-threatening or Disabling) Hematological Toxicities
Hematology evaluation included hemoglobin, hematocrit, red blood cell count, white blood cell with differential and platelet count. Differential included neutrophils, bands, lymphocytes, monocytes, eosinophils, and basophils. The intensity of each hematological toxicity was assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAEs). Hematological toxicities are summarized by Common Terminology Criteria (CTC) V3.0 Maximum Toxicity Grade.
Time frame: Week 1 through Endpoint (variable based on disease progression or toxicity
Population: ITT population (i.e., participants who had at least one dose of study medication)
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Intravenous Topotecan and Carboplatin | Grade 4 (Life-threatening or Disabling) Hematological Toxicities | Thrombocytopenia | 2 participants |
| Intravenous Topotecan and Carboplatin | Grade 4 (Life-threatening or Disabling) Hematological Toxicities | Anemia | 2 participants |
| Intravenous Topotecan and Carboplatin | Grade 4 (Life-threatening or Disabling) Hematological Toxicities | Neutropenia | 4 participants |
| Intravenous Topotecan and Carboplatin | Grade 4 (Life-threatening or Disabling) Hematological Toxicities | Leukopenia | 0 participants |
Secondary
Overall Survival, Calculated as the Number of Subjects Who Died From the Start of Treatment Until Follow-up
Overall survival is defined as the time from the start of treatment until death due to any cause. The study was terminated after the dose-finding run-in component was completed because of slow recruitment and acknowledgement of a competing Phase II study. Data not available, as the activity stage of the study was not conducted.
Time frame: Week 1 up to maximum of Day 519
Secondary
Response Duration
Duration of response is calculated as the time from first documented partial or complete response until first documented sign of disease progression or death. The study was terminated after the dose-finding run-in component was completed because of slow recruitment and acknowledgement of a competing Phase II study. Data not available.
Time frame: From time of partial or complete response to disease progression/death
Secondary
Time to Progression
Time to progression is defined as the time from the start of treatment until the first documented sign of disease progression or death due to any cause, if sooner. The study was terminated after the dose-finding run-in component was completed because of slow recruitment and acknowledgement of a competing Phase II study. Data not available.
Time frame: From start of treatment to disease progression/death
Secondary
Time to Response
Time to response is calculated as the time from the start of treatment until first documented evidence of partial or complete response. The study was terminated after the dose-finding run-in component was completed because of slow recruitment and acknowledgement of a competing Phase II study. Data not available, as the activity stage was not done.
Time frame: From start of treatment to evidence of partial or complete response